CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology. The company develops conditionally activated biologics intended to act in the tumor microenvironment, using its PROBODY and related platform approaches in both cancer and selected non-oncology research programs. Its pipeline includes CX-904, a bispecific T-cell engager directed at EGFR and CD3; CX-2051, a conditionally activated ADC being studied for EpCAM-expressing epithelial cancers, including colorectal cancer; CX-801, an interferon alpha-2b PROBODY cytokine; CX-2029, a conditionally activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. CytomX also has collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, Moderna, and Merck. Founded in 2008, the company is based in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CTMX
|
$2.85
|
-16.7% Downside
|
Fair
|
$12.50
|
265.0% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-12.0x
|
2.3x
|
21.0x
|
766.3 M
|
401.8 M
|
0.4%
|
85.6%
|
9.4
|
—
|
129.0%
|
